ADViRNA is a private contract research organization (CRO) that specializes in RNA interference (RNAi) solutions for gene silencing. They provide products and services to academic labs, biotech companies, and pharmaceutical teams to help them study and manipulate gene activity for research and therapeutic discovery
Self-deliverable RNAi (sdRNAi) Technology: ADViRNA's core proprietary technology involves chemically modified siRNAs (small interfering RNAs) that can enter cells and tissues without t...he need for traditional, often toxic, transfection reagents or formulations. This allows for efficient gene knockdown in hard-to-transfect cell types, including primary and stem cells, both in vitro and in vivo.
Oligonucleotide Design and Synthesis: The company offers custom design and synthesis of siRNAs and antisense oligonucleotides (ASOs), incorporating chemical modifications for enhanced stability and efficacy.
Screening and Validation: ADViRNA provides high-throughput screening services to identify and validate effective oligonucleotides for target genes.
HYBRID-ON™ Assay: This proprietary, highly sensitive assay is used for the detection and quantification of modified siRNAs and ASOs in complex biological samples (like tissue and plasma), which is crucial for biodistribution and pharmacokinetic/pharmacodynamic (PK/PD) analysis in preclinical development.
CRO Model: Operating as a boutique CRO, ADViRNA offers end-to-end support, from strategic experimental planning and custom assay development to in vivo study coordination, adapting to specific research needs and budgets.
